

AD _____

Award Number: W81XWH-08-1-0079

TITLE: Identification and functional characterization of somatic mutations in human microRNAs and their responsive elements in target genes in ovarian tumor tissues

PRINCIPAL INVESTIGATOR: Hua Zhao, Ph.D.

CONTRACTING ORGANIZATION: Health Research, Inc.
Buffalo, NY 14263

REPORT DATE: May 2009

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT:

☒ Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE (DD-MM-YYYY) 31/05/2009		2. REPORT TYPE Annual		3. DATES COVERED (From - To) 01 MAY 2008 - 30 APR 2009	
4. TITLE AND SUBTITLE Identification and functional characterization of somatic mutations in human microRNAs and their Responsive Elements in Target Genes in Ovarian Tumor tissues				5a. CONTRACT NUMBER W81XWH-08-1-0079	
				5b. GRANT NUMBER OC073116	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Hua Zhao, Ph.D. Email: hua.zhao@roswellpark.org				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Health Research, Inc. Elm and Carlton Sts Buffalo, NY 14263				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Epithelial ovarian cancer (EOC) continues to be the leading cause of the death among gynecological malignancies, owing to the lack of preventive strategies, early diagnostic methods or effective therapies. Detailed understanding of molecular changes, such as, somatic mutations, in ovarian cancer holds the promise of greatly contributing to the understanding of ovarian cancer pathogenesis, with obvious implications in development of new biomarkers, prevention strategies and therapy. Micro-RNAs (miRNAs) are endogenous non-coding ~22 nucleotide (nt) RNAs, whose expression appears to be elevated in normal tissues, compared to in tumors, suggesting that silencing of miRNA may be a hallmark of human cancers. MiRNA misexpression might be due to genetic mutations in miRNA genes and their responsive elements in target genes. To test this hypothesis, In the past year, we identified 7 genetic mutations in 50 selected human miRNA genes and their responsive elements in target genes in 75 OC tumor tissues. Their correlations with clinical outcome under investigation.					
15. SUBJECT TERMS microRNA ovarian cancer					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 6	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT UU	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	4
Reportable Outcomes.....	4
Conclusion.....	5

INTRODUCTION

Epithelial ovarian cancer (EOC) continues to be the leading cause of the death among gynecological malignancies, owing to the lack of preventive strategies, early diagnostic methods or effective therapies. Detailed understanding of molecular changes, such as, somatic mutations, in ovarian cancer holds the promise of greatly contributing to the understanding of ovarian cancer pathogenesis, with obvious implications in development of new biomarkers, prevention strategies and therapy. It is our hope that this investigation will yield signatures of somatic mutations that will help us predict disease outcome and possibly address crucial clinical management issues, such as identification of patients who will respond to standard chemotherapy, in need for alternate frontline drugs. Micro-RNAs (miRNAs) are endogenous non-coding ~22 nucleotide (nt) RNAs, whose expression appears to be elevated in normal tissues, compared to in tumors, suggesting that silencing of miRNA may be a hallmark of human cancers. MiRNA misexpression might be due to genetic mutations in miRNA genes and their responsive elements in target genes. To test this hypothesis, we plan to identify genetic mutations in selected human miRNA genes and their responsive elements in target genes in 75 OC tumor tissues and correlate somatic mutations in miRNA genes and their responsive elements in target genes with poor clinical outcome in EOC.

BODY

In the past one year, we have successfully sequenced 50 miRNAs in 75 OC tumor tissues. So far, seven novel somatic mutations were observed in seven primary or precursor miRNA genes.

Table. Somatic mutations in selected miRNA genes in ovarian tumor tissues			
miRNA genes	Nt	Location	MAF
Novel variants:			
<i>miR-199</i>	G/C	Pri-miRNA	0.036
<i>miR-191</i>	A/T	Pri-miRNA	0.018
<i>miR-29b-2</i>	T/C	Pri-miRNA	0.018
<i>miR-17</i>	A del	Pri-miRNA	0.036
<i>miR-92</i>	A/T	Pri-miRNA	0.009
<i>miR-26a</i>	C/T	Pri-miRNA	0.036
<i>miR-188</i>	G/A	Pri-miRNA	0.045

We will continue to perform sequencing analysis in more miRNAs in the next 6 months.

It is hypothesized that the presence of genetic variants in pri- or pre-miRNA, but not within the mature miRNA itself, could affect their secondary structure and thereby block processing into functional mature miRNA. To test this hypothesis, we used RNAhybrid to predict and calculate the most stable secondary RNA structure with the lowest free energy for the variant and the wildtype *pre-hsa-miR-188*. From the predicted secondary structures, a structure change was observed in the *pre-hsa-miR-188* A allele compared to

the G allele (Figure). The G allele created a base pairing, which strengthens the stability of the stem and changes the secondary structure of this pre-miRNA. The optimal free energy was increased from -39.20 Kcal/Mol for A allele to -41.60 kcal/Mol for G allele, suggesting a more stable secondary structure for G allele than A allele. Processing of




Figure 5. Secondary structure of miR-188 A and G alleles

miRNA precursors by the RNase Drosha requires the secondary hairpin structure characteristic of these RNA molecules and specific sequence elements within the pre-miRNA. To assess the effect of the predicted changes in secondary structure on mature miRNA expression, we cloned a wild-type or variant *hsa-miR-188* miRNA gene into the pcDNA3.1 expression plasmid (Invitrogen, CA) and transfected the constructs into PC-3 prostate cancer cell line. The expression levels of mature miRNAs were measured by Taqman based microRNA assays (Applied Biosystems). We found that the expression levels of mature hsa-miR-188 in the variant miRNA gene were over 3 times higher than those in wild-type. Using the PITA prediction algorithm, *MLH1* and *MSH2* are predicted as targets for *hsa-miR-188*. Therefore, our results suggest that a functional somatic mutation in the *pre-miR-188* gene might alter the expression of mature miRNA and, thereby, contribute to ovarian tumor development and cancer progression through regulating key ovarian cancer related genes.

KEY RESEARCH ACCOMPLISHMENTS

We have successfully sequenced 50 microRNAs in 75 OC tumor tissues. So far, seven novel somatic mutations were observed in seven primary or precursor miRNA genes.

WE found a functional somatic mutation in miR-188. This mutation could alter the expression of mature miRNA and, thereby, contribute to ovarian tumor development and cancer progression through regulating key ovarian cancer related genes.

REPORT OUTCOME

We are in the preparation of a manuscript to report our findings.

CONCLUSIONS

So far, the study moves smoothly. We don't expect any problems at current stage. We expect to begin data analysis on the correlations between somatic mutations and clinical outcome soon.